BioAlberta Celebrates Industry Leaders with Annual Achievement Awards at Health and Life Sciences Showcase Each year, Global Biotech Week and Life Sciences Week serve as a reminder of the enormous progress being made in Alberta’s thriving life sciences ecosystem. These…
ScaleReady Awards G-Rex® Grants to Advance Cell and Gene Therapy Manufacturing Across California ScaleReady, a joint venture formed by Wilson Wolf Manufacturing, Bio-Techne Corporation (NASDAQ: TECH), and CellReady, announced a major step forward in its commitment to advancing cell and…
BOTOX® Cosmetic Unveils “The One & Only” Campaign: A Celebration of Authenticity, Self-Expression, and Patient Stories A New Chapter for an Iconic Brand BOTOX® Cosmetic (onabotulinumtoxinA), one of the most recognizable names in aesthetics, has launched a new national campaign…
Alnylam Pharmaceuticals Launches $500 Million Convertible Senior Notes Offering to Strengthen Strategic Flexibility and Advance RNAi Pipeline Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the biotechnology pioneer recognized worldwide as the leader in RNA interference (RNAi) therapeutics, has announced the commencement of…
Cellworks Unveils Breakthrough in Predicting Chemo-Immunotherapy Benefit for Patients with Metastatic NSCLC Cellworks Group Inc., a leader in personalized therapy decision support and best-in-class patient-specific treatment response simulations (PTRS), has unveiled compelling findings from its landmark myCare-040 clinical study. The…
Purdue Pharma Expands Access to Low-Cost Opioid Use Disorder Treatment in U.S. Correctional Facilities On the occasion of International Overdose Awareness Day, Purdue Pharma L.P. (“Purdue”) announced an expansion of its public health initiative to make medication-assisted treatment for opioid…
Alnylam Advances Zilebesiran Into Global Phase 3 Cardiovascular Outcomes Trial Following Promising Phase 2 KARDIA Results Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a recognized leader in RNA interference (RNAi) therapeutics, announced a major milestone in its cardiovascular pipeline: the decision to…
BeOne Medicines Announces Positive Topline Results from Phase 1/2 Study of Sonrotoclax in Relapsed or Refractory Mantle Cell Lymphoma BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company focused on advancing innovative treatments for hematologic malignancies,…
Enveric Biosciences Advances Neuropsychiatric Pipeline with Successful Completion of Dose Range Finding Studies for Lead Candidate EB-003 Enveric Biosciences, Inc. (NASDAQ: ENVB), a biotechnology company pioneering next-generation neuroplastogenic small-molecule therapeutics, announced that it has successfully completed 7-day Dose Range Finding…
Fresenius Leads EASYGEN Consortium to Decentralize CAR-T Cell Therapy and Improve Patient Access Across Europe The global healthcare company Fresenius has announced the launch of a major new initiative aimed at reshaping the future of cell and gene therapy (CGT)…
Varian Completes Enrollment and Treatment in FAST-02 Clinical Trial, Marking Major Milestone for Flash Radiotherapy in Thoracic Bone Metastases Varian, a Siemens Healthineers company and a global leader in radiation oncology solutions, has announced the successful completion of both patient…
Merz Therapeutics Advances Migraine Research With Enrollment of First Patients in Two Global Phase III Clinical Trials for XEOMIN® (incobotulinumtoxinA) Merz Therapeutics GmbH, a neurology-focused specialty pharmaceutical company, announced a significant advancement in its clinical research program with the enrollment…